OINDPnews


Aptar Pharma banner

News

GSK to submit applications for UMEC/VI inhaler this year

GlaxoSmithKline says that it will begin regulatory submissions for its umeclidinium bromide (UMEC) and vilanterol (VI) dry powder inhaler for the treatment of COPD by the end of 2012. GSK is partnered with Theravance on this product, which will be delivered by the Ellipta inhaler. The two companies also announced the completion of the Phase 3 clinical program. … [Read more...] about GSK to submit applications for UMEC/VI inhaler this year

Hovione hires Conrad Winters as Director of Drug Product Development

Hovione has announced the appointment of Conrad Winters as Director, Drug Product Development. Winters most recently was Senior Director of the Compound Properties Group at Xenon Pharmaceuticals and previously held positions with Merck. Hovione VP of Corporate Research & Development Thomas Eisele commented, "We are very pleased to welcome Dr. Winters to Hovione. … [Read more...] about Hovione hires Conrad Winters as Director of Drug Product Development

Alexza gets EU GMP certificate for Adasuve manufacturing facility

Alexza Pharmaceuticals has received a EU Certificate of GMP Compliance of a Manufacturer subsequent to a May 2012 inspection by the Agencia Espanola de Medicamentos y Productos Sanitarios, the company has announced. Alexza plans to manufacture Adasuve Staccato loxapine at the facility in Mountain View, CA. Alexza says that the initial certificate will remain valid … [Read more...] about Alexza gets EU GMP certificate for Adasuve manufacturing facility

Positive Phase 3 results for Inavir DPI to prevent flu

Daiichi Sankyo has announced positive Phase 3 results for its Inavir laninamivir octanoate hydrate dry powder inhaler as a prophylactic antiviral. According to the company, the study found that Inavir produced statistically significant reductions in influenza infection compared to placebo among household members in contact with patients infected with influenza A or B, … [Read more...] about Positive Phase 3 results for Inavir DPI to prevent flu

Research firm predicts global asthma and COPD market will reach $47 billion by 2017

A new research report titled "Global Markets for Asthma & COPD Drugs" from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38 billion in 2012 and just over $47 billion in 2017. The report predicts that asthma drug sales alone will reach $20.2 billion in 2017, up from $15.3 … [Read more...] about Research firm predicts global asthma and COPD market will reach $47 billion by 2017

Nephron announces launch of OTC asthma inhalation product

Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as a substitute for the banned CFC Primatene Mist inhaler. According to the company, the product will be available at … [Read more...] about Nephron announces launch of OTC asthma inhalation product

Novartis reaffirms that respiratory research is to remain in Horsham, UK

According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to invest approximately £5 million to renovate some of the remaining buildings. In March 2011, Novartis announced significant personnel reductions at the site … [Read more...] about Novartis reaffirms that respiratory research is to remain in Horsham, UK